tools/dent refresh model ahead
ahead earn season publish updat model sever
compani account recent corpor action financ etc
well minor cadenc adjust includ updat
buy stock lag sinc beat/rais possibl due worri around deal
dilut slower global pmi data china trade war noisenon think overli
concern like set-up print analyst day june updat
model recent lasergen remain stake advanc analyt
acquisit deal boost posit genom could enhanc
growth profil dgg diagnost group unit time lasergen deal
could slightli dilut near-term ep initi thought back earli
first acquir stake suspect may off-set modest accret
well core oper upsid view like ep
forecast unchang
buy remain top pick compel absolut valu find
continu perplex disconnect stock price sartoriu
equiti valu ytd even though valu stake sartoriu
appreci ytd result net current mark/market
valu stake trade ev ebitda massiv
discount peer downsid risk seem low view updat model
reflect minor tweak quarterli cadenc overal ep forecast
buy updat model reflect recent equiti offer believ increment
fund mostli earmark support ind-en activ five enzyme-
base therapeut candid outsid pku valu alon
discoveri pipelin see larg free call option current level
buy rais ep reflect early-march
pre-releas point ep high-end guidanc help
strong start core revenu margin perspect led continu
posit momentum life scienc diagnost specif cphd
platform also rais ep account anticip accret
integr dna acquisit expect close still maintain
signific dri powder anoth sizabl acquisit expect focu
earn call
hold assum proce use repay term loan revolv rate
estim recent note offer rate save interest expens
 could accret forward ep
buy trade near trough rel multipl like
risk/reward updat model account anticip inventory-rel
headwind well expect dilut recent orametrix acquisit
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
histor project quarterli incom statement
million except per share data
page
pleas see import disclosur inform page report
histor net product incom expens share share analysisgross sg ebitda oper margin incom net growth analysisnet sg oper incom net dilut
histor project quarterli incom statement
million except per share data
page
pleas see import disclosur inform page report
histor resultshistor total net product expens share share analysisgross sg ebitda ebita oper incom net growth analysisnet gross sg net dilut
histor project quarterli incom statement
million except per share data
page
pleas see import disclosur inform page report
histor net product expens share share dilut dilut analysi product gross gross margin analysisnet dilut
histor project quarterli incom statement
million except per share data
page
pleas see import disclosur inform page report
histor net product incom incom share share analysisgross research sg ebitda oper margin incom net growth analysisnet gross research sg oper incom net dilut
histor project quarterli incom statement
million except per share data
page
pleas see import disclosur inform page report
histor net product expens share share analysisgross sg ebitda oper incom net growth analysisnet gross
histor project quarterli incom statement
million except per share data
page
pleas see import disclosur inform page report
histor total preciou net preciou product incom share share analysi net preciou metal gross research sg ebitda oper incom net growth analysissal net preciou incom
leader protein engin enzym
product use commerci manufactur
food ingredi in-vitro diagnost assay
see under-appreci growth idea w/
scope drive revenue compound-annual-growth-rate thru expand
food ngs/ivd diagnost market drive futur
valu pipelin novel biotherapeut
expect partner asset
futur back-end gsk
price impli ev rev
valu pku asset
futur back-end royalti gsk
ivd/ng enzym rev
addit collabor nestl health scienc
addit partnership novel therapeut pipelin
price base ev revenu
valu pku asset
new codeevolv platform licens deal
biopharma client
minim traction ivd/ng assay market
higher expens support develop nestl option
exercis pku therapeut asset
price ev revenu valu
page
pleas see import disclosur inform page report
